Physician profile
Patrick Dominguez
NPI 1184891830
$10,744.51
in general payments reported to CMS, 2019-2025
29 companies · $2,623 in 2025
The $2,623 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.30 · 2020: $223 · 2021: $184 · 2022: $2,387 · 2023: $2,113 · 2024: $3,161 · 2025: $2,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,824.50 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,552.91 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $960.24 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $912.59 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $885.66 | 2019-2025 | |
| Genzyme Corporation | $834.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $619.62 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $569.55 | 2019-2025 | |
| Ucb, INC. | $527.55 | 2024-2025 | Bimzelx |
| Amgen INC. | $486.51 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $459.90 | 2022-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $400.09 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $355.28 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Incyte Corporation | $343.96 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $343.62 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $272.44 | 2023-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $252.19 | 2022-2023 | Ilumya, Absorica Ld, Winlevi |
| Mayne Pharma Commercial LLC | $191.67 | 2022-2025 | |
| Almirall LLC | $141.57 | 2022-2025 | Seysara, Klisyri |
| Vyne Pharmaceuticals INC. | $125.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.67 | 2023-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.66 | 2020-2025 | Jublia, Cabtreo, Arazlo |
| Journey Medical Corporation | $48.50 | 2022-2024 | |
| Organogenesis INC. | $38.00 | 2024 | |
| Botanix Sb INC | $30.99 | 2025 | Sofdra |
| Organon LLC | $24.42 | 2025 | Vtama |
| Lnhc, INC | $23.51 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $15.69 | 2022 | |
| Verrica Pharmaceuticals INC. | $14.74 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.